Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Infinityon Dec 22, 2022 7:23pm
312 Views
Post# 35188367

RE:Some new math for those that play around w math

RE:Some new math for those that play around w mathDJ,  If you are refering to the MDA issued on 29th November.  Page 6 has some answers to your questions.  Total evaluable patients are 43 at 90 Days.  And 29 out of the 43 have reached 450 Days.  28% of this 29 evaluable patients are CR.   Intermediate responders are still work im progress.   Total CR + IR is at 38% at 450 days.  That is very impressive.  

What I really find stunning is 99.9% Kill rate on 5 different major virus, that is stated on page 9 of the MDA of 29th Nov.  This is like fool proof guaranteed to work.  This is a huge threat to Pfizer, Moderna and J&J.  In addition the dosage required to kill the five viruses is considered relatively safe.    I am more excited about the 99.9% kill rate.  All the more reason NRC to be involved im the Animal testing.  Glad to know the compnay has already designed and produced workimg modeld of TLC 3000B .  And PHAC & NRC Will have this 1Q2023 for their testing.
<< Previous
Bullboard Posts
Next >>